Study of different biochemical markers: bikunin, follistatin and activin significance in different types of ovarian cancer

Gihan M Sharara(1), Samer M Zahran (2), Mohamed A El-Samra(3).
(1) Medical Biochemistry, Faculty of Medicine, Alexandria University,
(2) Medical Biochemistry, Faculty of Medicine, Tanta University,
(2) Obstetrics and Gynecology, Faculty of Medicine, Alexandria University

ABSTRACT

OVARIAN CANCER HAS the second highest incidence in gynecological cancers and is the fifth leading cause of cancer death among women in the world. Characterizing the pathways that regulate the growth of ovarian cells is necessary for understanding the events that lead to development of ovarian cancer. The aim of the present study was to evaluate the potential clinical implication of circulating Activin A, follistatin, bikunin, ovarian tissue urokinase Plasminogen Activator (uPA) and Smad-2 (fusion between Drosophila mothers against dpp (Mad) and C. elegans Sma) expression for diagnosis and progression of ovarian cancer. Subjects: The study was carried out on 75 women divided as follows: 15 women with serous ovarian carcinoma, 15 women with mucinous ovarian carcinoma, 15 women with serous ovarian cystadenoma, 15 fertile healthy women, 15 postmenopausal healthy women.

Methods: Serum levels of Activin A and Follistatin, and Plasma levels of Bikunin were estimated using ELISA. Urokinase plasminogen activator (uPA) was extracted from ovarian cancerous tissue and its levels estimated by ELISA. Detection of Smad2 mRNA in ovarian tissue was performed by Reverse Transcription – Polymerase Chain Reaction analysis (RT-PCR). Results: The levels of serum Activin A and Follistatin were found to be significantly higher in serous and mucinous ovarian carcinoma than in ovarian cystadenoma and controls (pre- and postmenopausal). Plasma levels of Bikunin were estimated to be significantly lower in patients with serous ovarian carcinoma and mucinous ovarian carcinoma than in controls and than patients with ovarian cystadenoma. In the present study, levels of uPA in ovarian tissue were significantly higher in serous ovarian carcinoma than in ovarian cystadenoma and controls. Levels of uPA were significantly higher in mucinous ovarian carcinoma than all other groups. Levels of uPA were found to be increased with progression of the stage of ovarian tumor. Correlation studies showed direct positive significant correlations between Activin A and Follistatin, Activin A and uPA, Follistatin and uPA. Also, Bikunin was found to be inversely correlated to Activin A, Follistatin and uPA. Smad-2 expression was detected in 75% of cases of serous ovarian cystadenocarcinoma, in 90% of mucinous ovarian carcinoma.

Conclusions: In summary, activin A induces the proliferation of both serous and mucinous ovarian carcinoma. Therefore, activin A may be regarded as both a
potential growth factor and a tumor marker. The significantly elevated levels of serum follistatin (Activin – binding protein) in ovarian carcinoma indicated that activin is free and this modulated its signal transduction as illustrated by the expression of Smad-2 in 90% of mucinous ovarian carcinoma and in 75% of serous cystadenocarcinoma. The present study shows that the activin/Smad signaling pathway is functional in ovarian cancer cells which most probably promotes tumor growth. It is proposed that Smad-2 increased the levels of uPA which is a proteolytic enzyme that enhances tumor growth, progression, invasion and metastases. Plasma bikunin concentration might be a strong and independent favorable prognostic marker for ovarian cancer. It may be concluded that bikunin might attenuate Activin A-elicited signaling cascades in ovarian cancer this probably suppresses uPA expression. Treatment with bikunin may be beneficial to delay the appearance of metastatic disease and/or combined with cytotoxic agents to improve treatment efficacy in advanced ovarian cancers.

**INTRODUCTION**

OVARIAN cancer is considered the second highest incidence in gynecological cancers, ranks first in gynecologic cancer-related mortality, and is the fifth leading cause of cancer death among women world-wide. If ovarian cancer is detected early, more than 93% of patients survive ≥ 5 years; however, more than 75% of cases are diagnosed at advanced stages with a poor prognosis for survival. Most ovarian cancers are believed to arise from the ovarian surface epithelium (OSE), a modified peritoneal mesothelium derived embryologically from the coelomic epithelium. Characterizing the pathways that regulate the growth of OSE cells is a necessary first step toward understanding the events that lead to uncontrolled cellular proliferation and the development of ovarian cancer.

There appears to be a decreased risk of ovarian neoplasia with circumstances that decrease ovulatory frequency such as increased parity, breast feeding, and oral contraceptive use, whereas some studies seem to show an increased risk with the use of infertility drugs, although this finding remains controversial. These epidemiological findings suggest that suppression of folliculogenesis may be an important factor in decreasing the risk of epithelial ovarian cancer.

Activin A is a dimeric protein member of the transforming growth factor beta (TGFβ) superfamily composed of two β-subunits, βA-βA (activin A), βB-βB (activin B), or βA-βB (activin AB). It is synthesized by a variety of organs including normal endometrium. Activin A acts as an important regulator of cell growth and differentiation. Activin was originally identified as an inducer for follicle-stimulating hormone (FSH) from the pituitary, and it has a central
role in the regulation of the reproductive axis\(^6\). Follistatin is a soluble secreted glycoprotein that suppresses the release of FSH by binding to Activin and inhibiting its interaction with Activin receptors\(^5\).

However, as Activin is produced locally in the ovary, it has been hypothesized that it may act via an autocrine/paracrine mechanism to regulate ovarian function \(^5\). Activin mediates its cellular effects through heterodimeric complexes of type I and II Activin serine/threonine kinase receptors. The importance of the Activin in regulating cell proliferation and possibly ovarian tumor development has been suggested by Fukuda et al; in 1998\(^8\). To transmit the signal intracellularly, type I receptors activate a member of the SMAD family, which then translocates to the nucleus. Based on structural and functional characteristics, the Smad family is divided into three distinct classes: receptor-regulated Smads (R-Smads), common-mediator Smads (Co-Smads), and inhibitory Smads (I-Smads). R-Smads include Smad2 and 3, which are specifically recognized by activin and TGFβ type I receptors, and Smad1, 5, and 8, which are used by bone morphogenetic proteins (BMP) receptors\(^9\).

Receptor-regulated Smads, become phosphorylated by activated type I receptors and form heteromeric complexes with a common-partner Smad4, which translocates into the nucleus to control gene transcription. In addition to these signal transducing Smads, inhibitory Smads have been identified that inhibit the activation of receptor-regulated Smads.\(^10\,11\) Once in the nucleus, both R-Smad and Co-Smad may participate in DNA binding and recruitment of transcriptional cofactors\(^11\). Stimulation by activin results in the formation of complexes that contain forkhead activin signal transducer-1 (FAST-1), Smad2, and Smad4. Smad2 associates directly with FAST-1, whereas Smad4 contributes additional DNA binding specificity and transcriptional activation functions to the complex\(^12\).

Moreover, once recruited to specific elements, both Smad2/3 and Smad4 can activate transcription by recruiting additional co-activators that have histone acetyl transferase activity such as CBP/p300\(^13\). Alternatively, they can recruit corepressors such as TGIF or Ski family members, which in turn bind histone deacetylases \(^14\). Thus, Smads can positively or negatively regulate transcription of specific genes in response to activin/TGFβ signaling\(^8\). Thus, Smads play a critical role in transmitting the intracellular signal of TGFβ family ligands, including Activin A. Therefore, Smad-2 might explain the role of activin A in ovarian cancer\(^9\).

Considering the critical role Smads play in transmitting the intracellular signal of TGFβ family ligands, it is not surprising that cells regulate the availability of Smad at multiple levels. For example, Smad2 access to the type I receptor is modulated by a protein named Smad anchor for receptor activation (SARA), which binds unphosphorylated Smad2, thereby masking its nuclear localization signal and maintaining a cytoplasmic distribution. Upon receptor activation,
SARA interacts with the type I receptor to facilitate Smad2 phosphorylation and activation. As a result, Smad2 dissociates from SARA and complexes with Smad4, after which the complex translocates to the nucleus\(^9\).

Follistatin (FS) was first identified as a follicle-stimulating hormone inhibiting substance (i.e., structurally distinct from inhibin) present in ovarian follicular fluid\(^15\). It has since been shown to be a multifunctional regulatory protein exerting a majority of its effects via neutralization of activin. FS is a monomeric binding protein that regulates activin activity by forming an inactive complex. FS plays a role as a tissue regulator in the gonad, pituitary gland, pregnancy membranes, vasculature, and liver\(^16\). It is also essential for normal development.

FS is a single-chain polypeptide with a structure unlike activin or inhibin. Alternative splicing events, proteolytic cleavage and variable glycosylation lead to a vast array of possible FS isoforms found within various biological fluids\(^16\). FS in the circulation is most likely full-length FS 315 whereas FS in follicular fluid is predominately processed. Nearly all FS in circulation is bound to activin, and FS most likely acts as an autocrine/paracrine rather than endocrine factor in a number of tissues to regulate activin and other TGF-β superfamily members\(^9\).

FS is commonly found colocalized within a tissue with activin subunits or activin receptors. Activin/FS complexes may also bind extracellular matrix components thus forming reservoirs of activin/FS. Within the circulation, 70 - 90% of FS exists in the bound state\(^17\). FS binds to the common αA and βB subunits of activin and inhibin. Therefore, activin has two binding sites for FS (i.e., one activin dimer and two FS monomers make up the activin-FS complex), whereas inhibin has only one\(^17\). Activin A, AB, or B each binds FS with similar affinity. Since inhibin contains only one β-subunit, it binds FS with a lower affinity\(^18\).

FS does not bind activin exclusively. It can bind other members of the TGF-β superfamily, including BMP-4 and BMP-7\(^19\). It is also capable of binding the serum protein α2-macroglobulin, itself another binding protein for activin\(^19\).

FS has a strong affinity for heparan sulfate and can associate with heparan sulfate proteoglycans on cell surfaces\(^20\). Following binding to cell surface proteoglycans, activin/FS complexes can be rapidly endocytosed by lysosomal enzymes\(^21\).

The high affinity of activin-FS interaction approaches irreversibility due to its slow dissociation rate, rendering the bound activin unavailable for binding to its own (activin-RII/RIIB) receptor. The bound complex consists of two FS molecules for each activin ß/ß homodimer\(^9\).

The biological effects of activin A are counteracted by follistatin\(^22\), which is a high affinity extracellular binding protein for activin A\(^23\). Thus, follistatin modulates activin signaling even before it binds to its receptor, thus provides the first line of regulatory action of activin-A\(^9\). However, clinical data linking activin
A and follistatin are lacking and it is unknown whether their serum concentrations have any correlation with carcinoma cell differentiation. In addition, circulating activin appears to be bound to FS virtually irreversibly, suggesting that for endocrine activin to have distant actions it would have to be released from FS by some proteolytic mechanism. Such a mechanism has been identified for the related BMPs, in which bioactive BMP is released by cleavage of its binding protein, chordin, by the metalloproteinase, tolloid. Until this type of mechanism is identified for activin, most attention has been, and will likely continue to be, focused on the local autocrine/paracrine actions of activin.

Bikunin is a multifunctional glycoprotein, chondroitin sulfate-containing plasma protein synthesized in the liver. In vitro, it has been shown to inhibit proteases. It is a Kunitz-type protease inhibitor and has additional activities, but its biological function is still unclear. The processes of ovarian cancer dissemination are characterized by altered local proteolysis, cellular proliferation, cell attachment, and invasion. Thus Bikunin could be involved in the pathogenesis of ovarian cancer progression and peritoneal dissemination.

Invasion and metastasis of solid tumors require proteolytic enzymes that degrade the extracellular matrix and basement membranes. Among the proteases involved are the plasminogen activators, of which urokinase-type plasminogen activator (uPA) has been suggested to play a central role. Binding of uPA to the uPA receptor (CD87) activates the protease and catalyzes the conversion of plasminogen to plasmin, which subsequently activates type IV collagenase, or directly degrades extracellular matrix proteins such as fibrin, lamin, laminins, and proteoglycans. uPA has been associated with disease outcome as statistically independent prognostic markers in breast, lung, colon, kidney, and gastrointestinal cancers. Thus uPA could have a role in the pathogenesis of ovarian cancer progression.

The aim of the present study is to evaluate the potential clinical implication of circulating Activin A, follistatin, bikunin, endometrial tissue uPA and Smad-2 expression for diagnosis and progression of ovarian cancer.

SUBJECTS & METHODS

The study was carried out on 75 women admitted to Alexandria University Gynecology Hospital divided into the following groups: group 1: 15 women with serous ovarian carcinoma, group 2: 15 women with mucinous ovarian carcinoma, group 3: 15 women with serous ovarian cystadenoma, group 4: 15 fertile premenopausal healthy women, and group 5: 15 postmenopausal healthy women. Patient and disease characteristics of ovarian cancers are shown in table (1).
Table (1) Patient and Disease Characteristics of Ovarian Cancers

<table>
<thead>
<tr>
<th></th>
<th>Group 1: Serous ovarian carcinoma</th>
<th>Group 2: Mucinous ovarian carcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AGE:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>24 – 68 years</td>
<td>45 – 77 years</td>
</tr>
<tr>
<td>Median</td>
<td>44 years</td>
<td>60 years</td>
</tr>
<tr>
<td><strong>Number of patients without metastasis</strong></td>
<td>7</td>
<td>8</td>
</tr>
<tr>
<td><strong>Number of patients with metastasis</strong></td>
<td>8</td>
<td>7</td>
</tr>
</tbody>
</table>

All the included cases will be subjected to the following:

I. **Thorough history taking and clinical examination.**

II. **Laboratory investigations included**

1. **Serum levels of activin A** were estimated using ELISA\(^{(29)}\).
2. **Serum levels of follistatin** were estimated using the Quantikine Follistatin Immunoassay ELISA \(^{(30)}\).
3. **Plasma levels of bikunin** were estimated using ELISA (On EDTA)\(^{(31)}\).
4. **Tissue Collection and Extraction for uPA**\(^{(32)}\). Tissue samples were collected during surgery and stored in liquid nitrogen for further analysis. 500 mg wet weight of ovarian tissue were pulverized in the frozen state by a micro-dismembrator (Braun-Melsungen, Melsungen, Germany) and resuspended in a buffer containing 0.02 M Tris-HCl (pH 8.5), 0.125 M NaCl, and 1% Triton X-100 under gentle rotation at 4°C. The lysate was centrifuged for 45 min at 4°C, and an aliquot of the supernatant was assayed for protein concentration using the BCA Protein Assay reagent kit (Pierce, Rockford, IL)\(^{(32)}\).
5. **Detection of Smad2 mRNA by RT-PCR analysis**\(^{(1, 33)}\). Total RNA were obtained from fresh-frozen ovarian tissues during surgery from all patients \(^{(33)}\). Total cytoplasmic RNA for RT-PCR was isolated from ovarian cancer tissue using the single-step guanidinium isothiocyanate method \(^{(1)}\). Complementary DNA (cDNA) was synthesized from 10 µg of total cellular RNA by reverse transcription with Moloney murine leukemia virus reverse transcriptase (Life Technologies, Inc.) using random hexamers as primers\(^{(33)}\). RT-PCR was used to detect expression of smad2 target gene \(^{(30)}\).
cycles: 35 sec at 94 C, 35 sec at 59.5 C, 35 sec at 72 C. The Smad2 sense and antisense primers were used. The PCR mixture contained 50 mM Tris (pH 9.0), 50 mM KCl, 1.5 mM MgCl2, 0.01% gelatin, 100 ng of each primer, and 1 unit Taq polymerase (Life Technologies, Inc.). After an initial denaturation at 94°C for 5 min, amplification was carried out for 30 cycles at 94°C for 30 s, 55°C for 1 min, and 72°C for 1 min, followed by a final elongation step at 94°C for 2 min, 55°C for 2 min, and 72°C for 10 min. The PCR products were electrophoresed on a 2% agarose gel and stained with ethidium bromide.

**STATISTICS:** The values of the measured parameters were expressed as mean ± SD. The difference between groups was determined using ANOVA test (F-test). Pearson's correlation coefficient was performed for detection of the possible relation between the laboratory and biochemical variables. P<0.05 values were considered significant. All statistical analyses were processed using SPSS for windows, version 8.0.

### RESULTS

**Table (2): Serum Levels of Activin-A in the Studied Groups**

<table>
<thead>
<tr>
<th>Activin A (pg/ml)</th>
<th>Group 1 Serous ovarian carcinoma</th>
<th>Group 2 Mucinous ovarian carcinoma</th>
<th>Group 3 Serous cystadenoma</th>
<th>Group 4 Control premenopausal</th>
<th>Group 5 Control postmenopausal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>15</td>
<td>15</td>
<td>15</td>
<td>15</td>
<td>15</td>
</tr>
<tr>
<td>Mean</td>
<td>1417.7</td>
<td>1604.33</td>
<td>1244.4</td>
<td>621.6</td>
<td>637.6</td>
</tr>
<tr>
<td>SD</td>
<td>62.56</td>
<td>63.49</td>
<td>69.07</td>
<td>50.69</td>
<td>57.80</td>
</tr>
<tr>
<td>Range</td>
<td>1296-1480</td>
<td>1530-1690</td>
<td>1160-1339</td>
<td>558-685</td>
<td>580-730</td>
</tr>
<tr>
<td>F</td>
<td>299.72</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P</td>
<td>0.0001*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Significant at p< 0.05 between group 1 and both group 3 and controls; between group 2 and all other groups.

**Table (3): Serum Levels of Follistatin in the Studied Groups**

<table>
<thead>
<tr>
<th>Follistatin (pg/ml)</th>
<th>Group 1 Serous ovarian carcinoma</th>
<th>Group 2 Mucinous ovarian carcinoma</th>
<th>Group 3 Serous cystadenoma</th>
<th>Group 4 Control premenopausal</th>
<th>Group 5 Control postmenopausal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>15</td>
<td>15</td>
<td>15</td>
<td>15</td>
<td>15</td>
</tr>
<tr>
<td>Mean</td>
<td>835.7</td>
<td>1276.67</td>
<td>642.2</td>
<td>392.0</td>
<td>396.0</td>
</tr>
<tr>
<td>SD</td>
<td>39.88</td>
<td>266.79</td>
<td>65.42</td>
<td>70.49</td>
<td>54.13</td>
</tr>
<tr>
<td>Range</td>
<td>780-890</td>
<td>980-1600</td>
<td>550-780</td>
<td>320-500</td>
<td>320-470</td>
</tr>
<tr>
<td>F</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.0001*</td>
</tr>
</tbody>
</table>

* Significant at p< 0.05 between group 1 and both group 3 and controls; between group 2 and all other groups.
Table (4): Plasma Levels of Bikunin In The Studied Groups

<table>
<thead>
<tr>
<th>Bikunin (µg/ml)</th>
<th>Group 1 Serous ovarian carcinoma</th>
<th>Group 2 Mucinous ovarian carcinoma</th>
<th>Group 3 Serous cystadenoma</th>
<th>Group 4 Control premenopausal</th>
<th>Group 5 Control postmenopausal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Mean</td>
<td>11.55</td>
<td>11.08</td>
<td>16.16</td>
<td>18.94</td>
<td>18.80</td>
</tr>
<tr>
<td>SD</td>
<td>0.31</td>
<td>0.45</td>
<td>0.82</td>
<td>0.84</td>
<td>0.66</td>
</tr>
<tr>
<td>Range</td>
<td>11.1-12.1</td>
<td>10.5-11.6</td>
<td>15.1-17.1</td>
<td>18.1-20.1</td>
<td>18.2-19.7</td>
</tr>
<tr>
<td>F</td>
<td></td>
<td>231.22</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P</td>
<td></td>
<td>0.001*</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* significant at p< 0.05: significantly lower in group 1 and group 2 than in controls and than group 3, and also plasma bikunin levels were found to be significantly lower in group 3 than in controls.

Table (5): Levels of uPA in Endometrial Tissue in the Studied Groups

<table>
<thead>
<tr>
<th>uPA (ng/mg protein)</th>
<th>Group 1 Serous ovarian carcinoma</th>
<th>Group 2 Mucinous ovarian carcinoma</th>
<th>Group 3 Serous cystadenoma</th>
<th>Group 4 Control premenopausal</th>
<th>Group 5 Control postmenopausal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Mean</td>
<td>3.82</td>
<td>5.45</td>
<td>2.45</td>
<td>0.614</td>
<td>1.22</td>
</tr>
<tr>
<td>SD</td>
<td>0.44</td>
<td>0.30</td>
<td>0.32</td>
<td>0.25</td>
<td>0.36</td>
</tr>
<tr>
<td>Range</td>
<td>3.2 - 4.4</td>
<td>5.0 - 5.9</td>
<td>2.0 – 2.9</td>
<td>0.24 – 1.00</td>
<td>0.5 – 1.7</td>
</tr>
<tr>
<td>F</td>
<td></td>
<td>338.86</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P</td>
<td></td>
<td>0.001*</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Significant at p < 0.05: significantly higher in group 1 and group 2 than in controls and than group 3, and significantly higher in group 3 than in controls.

Table (6): The Correlation Study between the Studied Groups

<table>
<thead>
<tr>
<th></th>
<th>Activin A</th>
<th>Follistatin</th>
<th>Bikunin</th>
<th>uPA</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Activin A</strong></td>
<td>r = 1.0</td>
<td>r = 0.87</td>
<td>r = - 0.92</td>
<td>r = 0.96</td>
</tr>
<tr>
<td>* p = --</td>
<td>p = 0.001</td>
<td>p = 0.001</td>
<td>p = 0.0001</td>
<td>p = 0.001</td>
</tr>
<tr>
<td><strong>Follistatin</strong></td>
<td>r = 0.87</td>
<td>r = 1.0</td>
<td>r = - 0.86</td>
<td>r = 0.93</td>
</tr>
<tr>
<td>* p = 0.001</td>
<td>p = --</td>
<td>p = 0.001</td>
<td>p = 0.001</td>
<td>p = 0.001</td>
</tr>
<tr>
<td><strong>Bikunin</strong></td>
<td>r = - 0.92</td>
<td>r = - 0.86</td>
<td>r = 1.0</td>
<td>r = - 0.95</td>
</tr>
<tr>
<td>* p = 0.001</td>
<td>p = --</td>
<td>p = 0.001</td>
<td>p = --</td>
<td>p = 0.001</td>
</tr>
<tr>
<td><strong>uPA</strong></td>
<td>r = 0.96</td>
<td>r = 0.93</td>
<td>r = - 0.95</td>
<td>r = 1.0</td>
</tr>
<tr>
<td>* p = 0.001</td>
<td>p = 0.001</td>
<td>p = 0.001</td>
<td>p = --</td>
<td></td>
</tr>
</tbody>
</table>

* Significant at p< 0.05
The levels of Activin A were found to be significantly higher in serous ovarian carcinoma than in ovarian cystadenoma and controls. Levels of Activin A were significantly higher in mucinous ovarian carcinoma than all other groups, including serous ovarian carcinoma. Also levels of Activin were significantly higher in serous ovarian cystadenoma than controls. \(F= 299.73, \ p = 0.0001\) (Table 2).

In the present study, levels of serum Follistatin were found to be significantly higher in serous ovarian carcinoma than in ovarian cystadenoma and controls (pre- and postmenopausal). Levels of Follistatin were significantly higher in mucinous ovarian carcinoma than all other groups, including serous ovarian carcinoma. Also levels of Follistatin were significantly higher in serous ovarian cystadenoma than controls. \(F= 54.75, \ p = 0.0001\) (Table 3)

Plasma levels of Bikunin were found to be significantly lower in patients with serous ovarian carcinoma (Group 1) and mucinous ovarian carcinoma (group 2) than in controls (group 4 and 5) and than patients with ovarian cystadenoma, and also serum Bikunin levels were found to be significantly lower in ovarian cystadenoma than in controls. \(F=231.22, \ p =0.0001\) (Table 4).

In the present study, levels of uPA in ovarian tissue were significantly higher in serous and mucinous ovarian carcinoma than in ovarian cystadenoma and controls (pre- and postmenopausal). Also levels of uPA were significantly higher in ovarian carcinoma with metastases than those without metastases. Levels of uPA were found to be increased with progression of the stage of ovarian tumor. \(F= 338.86, \ p = 0.001\) (Table 5).

On performing correlation studies between the studied parameters, direct positive correlation was found between Activin and Follistatin (correlation co-efficient \(r = 0.87, \ p < 0.001\)). Also a significant negative correlation was detected between Activin and Bikunin (correlation co-efficient \(r = - 0.92, \ p < 0.001\)), and between Follistatin and Bikunin (correlation co-efficient \(r = - 0.86, \ p < 0.001\)). Finally, uPA was found to be significantly positively correlated with activin A, Follistatin \(r = 0.96, 0.93\), respectively at \(p < 0.01\) and inversely correlated with bikunin \(r = - 0.95\) at \(p < 0.01\) (Table 6).

**Results of Smad-2 mRNA by RT-PCR (Figure 1)**

Total RNA obtained from ovarian tumors (serous, mucinous ovarian carcinoma and cystadenoma) was reverse transcribed as described in "Methods." The resulting cDNA was PCR-amplified using primers specific for Smad2. Positive control (+), plasmids encoding the cDNA for Smad2; negative control (-), water. Figure (1) shows the result of RT-PCR of 10 ovarian tumors which highly expressed Smad-2. Smad-2 expression was found in 75% of cases of serous ovarian cystadenocarcinoma (group 1), in 90% of mucinous ovarian carcinoma (group 2), in 30% of cystadenoma (group 3) and only 10% of the controls expressed Smad-2 (group 4 and 5).
In the current study, Activin A levels were found to be increased in the serum of subjects with epithelial serous cystadocarcinoma and mucinous ovarian carcinoma than benign cystadenoma and controls. Activin A secretion correlated significantly with tumor type (P < 0.05); mucinous tumors secreted significantly higher levels of activin A than serous tumors. Mucinous tumors secreted the highest level of activin A. Activin is thought to induce proliferation in epithelial ovarian carcinoma cell lines. (34)

Elevated serum activin A levels in subjects with epithelial ovarian carcinoma suggest that activin may be a factor contributing to tumorigenesis in these patients and that it might have a possible role in ovarian cancer (34). Increased activin in ovarian tumors may represent an early event that leads to epithelial proliferation. (35, 36) Thus, Activin A may potentially serve as a
tumor marker in the diagnosis and screening of serous and mucinous tumors.

Ovarian cancer cells proliferate in association with high levels of Activin A, which were correlated with advanced stages of the disease, especially with mucinous carcinoma. Activin A is thought not only to stimulate the proliferation of ovarian cancer cells but also has the selective advantage for allowing tumor cell survival because of the positive angiogenic and immunosuppressive effects that allow it to promote tumor growth. In addition, activin A enhances the invasive properties of ovarian cancer cells; most likely through up-regulation of cellular matrix metalloproteinases. Once tumorigenesis is initiated, however, activin signaling may enhance the metastatic process. (1)

In the present study, the serum levels of Follistatin increased significantly in patients with mucinous and serous ovarian carcinomas than cystadenoma and controls. This increase indicates that the Activin is not bound to its binding protein, follistatin. This keeps the activin free, thus increasing the effect of activin on induction of proliferation of ovarian cancer cells.

Follistatin (FS), an activin binding and neutralizing protein, was found to decrease proliferation in the cell lines producing activin. (34) In patients with advanced stage of tumors and hematological malignancies, free follistatin levels were elevated. (47)

Activin signaling is regulated extracellularly by FS whereas a number of intracellular proteins act to modulate cellular responses to these activin signals. It is therefore the balance between activin and all of its modulators, rather than the actions of any one component, that determines the final biological outcome. (9)

Ovarian cancer cells receive a myriad of signals from molecules present in ascitic fluid or in the tumor microenvironment, and the interpretation of these signals ultimately results in the cellular response (e.g. grow, die, migrate, invade). (11)

As regards Smad 2 mRNA it was found to be highly expressed in ovarian mucinous carcinoma (90%) and in serous ovarian cystadenocarcinoma (75%). This expression positively correlated with levels of activin A. These data provide a better understanding of the mechanism of action of the activin in the ovarian carcinoma. Similar results were detected in which Smad 2 mRNA levels were increased during 48 h treatment with activin A (50 ng ml(-1)). (38)

Activin A performs its signal transduction via Smads, which are pivotal intracellular nuclear effectors. Ligand-induced activation of activin A receptors with intrinsic serine/threonine kinase activity trigger phosphorylation of receptor-regulated Smads (R-Smads), whereas Smad2 and Smad3 are phosphorylated by TGF-β, and activin type I receptors, Smad1, Smad5 and Smad8, act downstream of BMP type I receptors. Activated R-Smads form heteromeric complexes with common-partner Smads (Co-Smads), e.g. Smad4, which translocate efficiently to the nucleus, where they regulate, in co-
operation with other transcription factors, coactivators and corepressors, the transcription of target genes\(^{(39)}\).

It is shown that the Activin/Smad signaling pathway is functional in ovarian cancer cells which most probably causes positive angiogenic and immunosuppressive effects that allow it to promote tumor growth\(^{(40)}\). In addition, Activin A enhances the invasive properties of ovarian cancer cells; most likely through up-regulation of cellular matrix metalloproteinases\(^{(41)}\), most probably through perturbation of the Smad pathway\(^{(41)}\).

The present study is among the few that evaluated the link between activin A and Smad pathway in ovarian cancer patients, rather than ovarian cell lines, since a significant positive correlation was found between Smad-2 mRNA and activin A. Perturbation of the Activin A/SMAD signaling pathway may result in progression of ovarian tumors through induction by Activin A\(^{(11)}\). The results of the present study suggest that activin/Smad pathway may contribute to the aggressive behavior of ovarian cancer cells\(^{(35)}\). Several studies\(^{(11, 35)}\) are in agreement with the present results. However, these studies were done on cell lines rather than patients.

Levels of uPA were elevated significantly in patients with serous and mucinous ovarian carcinoma than serous cystadenoma than controls, with highest levels in advanced stages of ovarian cancer.

In the present study, uPA concentrations were significantly higher in invasive tumors compared with low malignant potential tumors, which have been recognized as a separate entity, as the clinical course of these tumors is far more favorable when compared with their invasive counterparts. Similarly, uPA levels were higher in patients with metastases as compared with those without metastases.

These findings demonstrate that uPA is associated with the malignant progression of ovarian cancer. The results are consistent with the hypothesis that elevated levels of uPA may contribute to invasiveness and metastasis of ovarian cancer. These observations indicate a role of uPA in tumor progression and angiogenesis, and may be directly involved in cancer cell migration and invasion.

These results are in agreement with several other studies\(^{(42, 43)}\). Hoffmann et al.\(^{(44)}\) were also able to demonstrate prognostic relevance of uPA for ovarian cancer. In contrast, van der Burg et al.\(^{(45)}\) who assessed uPA and PAI-1 among 90 patients ranging from stage I to stage IV disease, reported no correlation of uPA and PAI-1 with PFS or OS. The negative findings of that study possibly are attributable to the different laboratory assays, extraction procedures, and cut off values used. It should be mentioned, however, that Šprem et al.\(^{(46)}\) detected higher average concentrations of uPA in primary ovarian tumors, but due to large variations between tumors in a small number of patients, these higher values were statistically insignificant.

Proteolytic destruction of the basement membrane and tumor surrounding is a prerequisite of invasion and metastasis of tumor cells. In this process, uPA plays an
important role because it is involved in the degradation of the components of the extracellular matrix and basement membrane. The serine protease uPA, in concert with its inhibitor PAI-1, promotes tumor cell adhesion, migration, and proliferation, as well as extracellular matrix degradation and, thus, facilitates tumor cell invasion and metastasis.

Tumor cell invasion is dependent on finely regulated extracellular proteolytic activity, which allows tumor cells to invade the extracellular matrix. Among the proteolytic enzymes involved in this process are PAs, whose expression in cultured cells is regulated by several types of growth factors and cytokines. Invasive tumor cells not only express cell-associated proteases but also secrete anti-proteases, preventing the overdigestion of the extracellular matrix, which leads to loss of cell attachment. The balance between proteolytic activity and inhibition is crucial in the invasive and metastatic event.

A positive correlation was found between Activin A and levels of uPA. Thus, enhanced production of uPA was found most probably in response to elevated production of Activin A. Activin A induced the increase of net PA, which might result in strong proteolytic activity in some specific sites, such as areas of cell-to-cell or cell-to-extracellular matrix contacts. For this reason, drugs that manipulate or suppress signal transduction on the PA system in malignant cells offer a potentially new approach to anti-cancer therapy.

Plasma Bikunin levels were significantly decreased in serous and mucinous ovarian cancer than in cystadenoma and controls. Lowest levels were found in patients with metastasis. Bikunin is a Kunitz-type protease inhibitor with tumor-suppressive potential in several malignant cell types, acting at the level of tumor invasion and metastasis. It was subsequently demonstrated that bikunin inhibits tumor invasion, at least in part, by a direct inhibition of plasmin activity as well as by inhibiting uPA. Mechanistic studies in several cell types demonstrated that bikunin interferes with an upstream target(s) of selected MAP kinase signaling processes such as phosphorylation of MEK and ERK, leading to overexpression of uPA.

It has been reported that in preclinical studies with several types of malignant cells, bikunin is an anti-invasive and anti-metastatic agent. In recently completed clinical studies, bikunin has been shown to stabilize disease progression in patients with advanced ovarian cancer. Bikunin specifically inhibits expression of uPA mRNA and proteins, the molecular mechanism underlying the tumor-suppressive effect of bikunin remains elusive.

In the present study, bikunin inhibits uPA in ovarian cancer. This is in agreement with other studies, but on cell lines rather than on patients. From the present study, it can be hypothesized that low levels of Bikunin in ovarian cancer patients releases the inhibition of expression of uPA thus causing increase in uPA levels. Also, the low levels of bikunin
in the ovarian cancer results in the stimulation of Activin A signaling as measured by the downstream signaling effector Smad2 expression. Furthermore, there was enhanced production of uPA in ovarian cancer cells in response to high levels of activin A secreted by these cancerous cells.

It can be suggested that bikunin may attenuate Activin A-elicited signaling cascades in ovarian cancerous cells and that probably provides the mechanism for the suppression of uPA expression. Thus, the up-regulation of the PA system in ovarian cancer cells is dependent upon activation of the Activin A-mediated ERK signal transduction cascade, which is downstream from an influx of extracellular calcium, and activation of tyrosine kinases and that bikunin can function as a non-voltage-sensitive calcium channel blocker(47).

The inverse correlation found between Bikunin and uPA as well as with Activin A is confirmed by the study by Hirashima Y et al. (28) in which expression of uPA and PAI-1 in the human ovarian cancer cell line HRA can be down-regulated by exogenous bikunin (bik), a Kunitz-type protease inhibitor, via suppression of transforming growth factor-beta1 (TGF-beta1) up-regulation and that overexpression of the bik gene can specifically suppress the in vivo growth and peritoneal dissemination of HRA cells in an animal model(28). The results suggest that low bikunin in ovarian carcinoma may be associated with poor prognosis. It is conceivable that testing for bikunin may identify patients with ovarian carcinoma who are at high risk for early disease severity and a poor prognosis(27). It is thought that plasma bikunin concentration is a strong and independent favorable prognostic marker for ovarian cancer(25).

Conclusions:

Ovarian cancer has the highest mortality rate of the gynecological malignancies primarily because of the lack of early detection of the disease. The identification of novel signaling pathways involved in ovarian cancer progression is critical to the development of better diagnostics and more efficacious therapeutics.

In summary, the data provided here clearly demonstrate that circulating activin A levels were elevated in a serous and mucinous ovarian carcinoma. Thus, activin A induces the proliferation of both serous and mucinous ovarian carcinoma. Therefore, Activin A may be regarded as both a potential growth factor and a tumor marker is warranted.

The significantly elevated levels of serum follistatin (Activin – binding protein) in ovarian carcinoma indicated that activin is free and this modulated its signal transduction as illustrated by the expression of Smad-2 in 90% of mucinous ovarian carcinoma and in 75% of serous cystadenocarcinoma. We show that the Activin/Smad signaling pathway is functional in ovarian cancer cells which most probably causes positive angiogenic and immunosuppressive effects that allow it to promote tumor growth. Also, evidenced by the present study, it is proposed that Smad-2 increased the levels of uPA which is a proteolytic enzyme that
enables tumor growth and progression as well tumor cell invasion and metastases.

Our data are the first to illustrate that low Bikunin levels were found to be associated with advanced ovarian cancer. It is postulated that Bikunin, a protease inhibitor, up regulated Activin (in the same manner that it up-regulated TGF-beta). These findings point to a novel role for bikunin in regulating the PA system and Activin A-mediated invasion. It is thought that plasma bikunin concentration might be a strong and independent favorable prognostic marker for ovarian cancer.

It can be concluded that bikunin might attenuate Activin A-elicited signaling cascades in ovarian cancer and that this probably provides the mechanism for the suppression of uPA expression. Treatment with bikunin may be beneficial as an adjuvant therapy to delay the appearance of metastatic disease and/or combined with cytotoxic agents to improve treatment efficacy in advanced ovarian cancers.

REFERENCES


Endocrinology to Signaling. A Paradigm for the New Millennium Experimental Biology and Medicine 2002; 227:724-752


44. Hoffmann G., Pollow K., Weikel W., Strittmatter H. J., Bach J., Schaffrath M., Knapstein P., Melchert F., Pollow B. Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters.


دراسة بعض الدلائل الكيميائية: الأكثفيين أو الفولستاتين والبيكينين في سرطان المبيض

جيهان شرارة، سامر محمود زهريان، محمد السمر،*،*،* 

قسم الكيمياء الحيوية الطبية- كلية الطب- جامعة الأسكندرية، **، دكتورة الكيمياء الحيوية الطبية- كلية الطب- جامعة طنطا، *** قسم النساء والتوليد- كلية الطب- جامعة الأسكندرية 

سرطان المبيض هو أحد الأورام الخبيثة الأكثر انتشارًا في العالم، التي تسبب الجهاز التناسلي الأنثوي وهو أول سبب للوفاة نتيجة سرطان الجهاز التناسلي الأنثوي. لذلك، دراسة الطرق الخاصة بالتحكم في تكاثر خلايا المبيض يساعد على اكتشاف حدوث وتدخيل سرطان المبيض.

الهدف من هذه الدراسة هو دراسة الأهمية الكيميائية لكل من الأكثفيين، أو الفولستاتين، البيكينين، منظري البروتينايبر بالأنسوجين، و سمام-2 في تشخيص وتدخيل سرطان المبيض في النساء.
وبذلك أجريت هذا البحث على 75 سيدة وقسوماً إلى 15 سيدة، يعانون من سرطان الغدي الكبيسي بال hútام، 10 سيدة، يعانون من سرطان المخاطي بال hútام، 15 سيدة، يعانون من رم الغدي الكبيسي بال hútام، 15 سيدة خصبة و أصحاء، و 15 أصحاء يعانون من انقطاع العرض.

لقد أجريت لهذا الغرض تحليلات ألكتيفية وأنماط قياسية مختلفة على ألكتيفات البلاسمونج، والتي تمثل النسبة من الانشار في الخلايا السرطانية بال hútام.

وقد تم بناء أن نسبة الألكتيفات وألفولستاتين في النسبة المئوية من سرطان الغدي الكبيسي بال hútام و السرطان المخاطي بال hútام وغير الأصحاء، وكذلك في السرطان المخاطي بال hútام. ونسبة سرطان الغدي الكبيسي بال hútام، والغموض، والไขض، والأسنان، ونسبة الرحم في الخلايا السرطانية بال hútام.

وقد تم بناء أن نسبة الألكتيفات وألفولستاتين في النسبة المئوية من حالات سرطان الغدي الكبيسي بال hútام، ونسبة 90% من حالات السرطان المخاطي بال hútام بينما كانت 30% من حالات رم الغدي الكبيسي بال hútام و 10% فقط من الأصحاء.

وقد تم بناء أن نسبة الألكتيفات وألفولستاتين في النسبة المئوية من حالات سرطان الغدي الكبيسي بال hútام، ونسبة 90% من حالات السرطان المخاطي بال hútام، بينما كانت 30% من حالات رم الغدي الكبيسي بال hútام و 10% فقط من الأصحاء.

وقد تم بناء أن نسبة الألكتيفات وألفولستاتين في النسبة المئوية من حالات سرطان الغدي الكبيسي بال hútام، ونسبة 90% من حالات السرطان المخاطي بال hútام، بينما كانت 30% من حالات رم الغدي الكبيسي بال hútام و 10% فقط من الأصحاء.

وقد تم بناء أن نسبة الألكتيفات وألفولستاتين في النسبة المئوية من حالات سرطان الغدي الكبيسي بال hútام، ونسبة 90% من حالات السرطان المخاطي بال hútام، بينما كانت 30% من حالات رم الغدي الكبيسي بال hútام و 10% فقط من الأصحاء.

وقد تم بناء أن نسبة الألكتيفات وألفولستاتين في النسبة المئوية من حالات سرطان الغدي الكبيسي بال hútام، ونسبة 90% من حالات السرطان المخاطي بال hútام، بينما كانت 30% من حالات رم الغدي الكبيسي بال hútام و 10% فقط من الأصحاء.